

Pomalidomide ▼

Pregnancy Prevention Programme

Woman of Non-Childbearing Potential Risk Awareness Form

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.

Approved by the Malta Medicines Authority on the 2nd of April 2026.

Reporting of Adverse Reactions

Suspected adverse reactions and medication errors should be reported either to:

ADR Reporting, The Medicines Authority, Post-Licensing Directorate,
Sir Temi Zammit Buildings, Malta Life Sciences Park,
San Gwann SGN 3000, Malta
Website: www.medicinesauthority.gov.mt
e-mail: postlicensing.medicinesauthority@gov.mt

or

Adalvo Limited
Malta Life Sciences Park,
Sir Temi Zammit,
Building 1, Level 4,
San Gwann Industrial Estate,
San Gwann, SGN 3000,
Malta
Email: pharmacovigilance@adalvo.com
Tel: +0040 727251514

RISK AWARENESS FORM FOR COUNSELLING THE PATIENT TO ENSURE THE PATIENT IS FULLY INFORMED ABOUT THE SAFE USE OF POMALIDOMIDE

This Risk Awareness Form is to assist you with counselling a patient before they commence pomalidomide treatment in order to ensure it is used safely and correctly. It must be completed for each female patient of childbearing potential prior to the initiation of their pomalidomide treatment. This form must be completed by a physician experienced in managing immunomodulatory drugs.

The purpose of the Risk Awareness Form is to protect patients and any possible fetuses by ensuring that patients are fully informed of and understand the risk of teratogenicity and other adverse drug reactions associated with the use of pomalidomide. It is mandatory that women of childbearing potential receive counselling and education to be made aware of the risks of pomalidomide as it is contraindicated in women of childbearing potential unless all terms of counselling are met.

The form should be retained with their medical records, and a photocopy provided to the patient. It is not a contract and does not absolve anybody from his/her responsibilities regarding the safe use of the product and prevention of foetal exposure.

Warning: Pomalidomide must not be taken during pregnancy, since a teratogenic effect in humans is expected. Pomalidomide is structurally related to thalidomide. Thalidomide is a known human teratogen that causes severe life threatening birth defects. Pomalidomide was found to be teratogenic in both rats and rabbits when administered during the period of major organogenesis. The conditions of the Pregnancy Prevention Programme must be fulfilled for all patients unless there is reliable evidence that the patient does not have childbearing potential.

If pomalidomide is taken during pregnancy, it is expected to cause severe birth defects death to an unborn baby.

Patient Details

Patient's First Name:

Patient's Last Name:

Date of Birth:

DD MM YYYY Counselling Date:*DD MM YYYY*

Did you inform your patient:	Woman of Non-Childbearing Potential
1) To not share the medicinal product with any other person.	<i>Tick</i>
2) That they should not donate blood during treatment (including during dose interruptions) and for at least 7 days following discontinuation of Pomalidomide.	<i>Tick</i>
3) That they should return the unused capsules to the pharmacist at the end of treatment.	<i>Tick</i>
4) Of hazards and necessary precautions associated with use of pomalidomide.	
5) Of the thromboembolic risk and possible requirement to take thromboprophylaxis during treatment with pomalidomide.	

Prescriber Confirmation

I have fully explained to the patient named above the nature, purpose and risks of the treatment associated with pomalidomide, especially the risks to women of childbearing potential.

I will comply with all my obligations and responsibilities as the prescriber of pomalidomide.

Prescriber's First Name:

Prescriber's Last Name:

Prescriber Signature:

Date:

DD MM YYYY

Patient: please read thoroughly and initial the adjacent box if you agree with the statement

I understand that severe birth defects may occur with the use of pomalidomide. I have been warned by my prescriber that any unborn baby has a high risk of birth defects and could even die if a woman is pregnant or becomes pregnant while taking pomalidomide.

I understand that pomalidomide will be prescribed ONLY for me. I must not share it with ANYONE.

I have read the pomalidomide Patient Brochure and understand the contents, including the information about other possible health problems (side effects) associated with the use of pomalidomide.

I know that I cannot donate blood while taking pomalidomide (including dose interruptions) or for at least 7 days after stopping treatment.

Patient initials

I understand that I must return any unused pomalidomide capsules to my pharmacy at the end of my treatment.

Patient initials

I have been informed about the thromboembolic risk and possible requirement to take thromboprophylaxis during treatment with pomalidomide.

Patient initials

I understand that my prescriber will provide me with a completed 'Prescription Authorisation Form' with each pomalidomide prescription, and that I must provide this to my pharmacy..

Patient initials

I understand that the 'Prescription Authorisation Form' contains non identifiable information about me, which will ensure pomalidomide is dispensed safely. The information may also be used by the Marketing Authorisation Holder, the distributor of the product and the Health Authority to evaluate the safe use of pomalidomide.

Patient initials

Patient Confirmation

I confirm that I understand and will comply with the requirements of the Pomalidomide Pregnancy Prevention Programme, and I agree that my prescriber can initiate my treatment with pomalidomide.

This form will be kept by your doctor. Your personal data collected by the marketing authorisation holder of Pomalidomide for the purpose(s) of managing the Pregnancy Prevention Programme.

Your personal data is used solely for the purpose of entering you into the pomalidomide Pregnancy Prevention Programme and is processed by the marketing authorisation holder (MAH) of the pomalidomide product you receive, its third-party service providers and any affiliates the MAH may have, for the purposes of compliance with the Risk Management Plan legal obligations and for storage purposes. Third party service providers include, for example, the distributor of the pomalidomide product you receive.

Your pharmacist can confirm the details of the MAH for the pomalidomide product you are given and this will also be mentioned on the packaging and package leaflet. Queries on how your personal data will be processed can be directed to the MAH in question, by consulting their publicly available information (e.g. on their website) which details how they process your personal data and provides a contact point for any queries in relation to their use of your personal data.

Patient Signature:

Date: *DD MM YYYY*

Statement of the interpreter (where appropriate)

I have interpreted the information above to the patient/parent to the best of my ability and in a way in which I believe she/he/they can understand. She/he/they agree to follow the necessary precautions to prevent an unborn child being exposed to pomalidomide

Interpreter Signature:

Date: *DD MM YYYY*